Impact of Bcl-2 proteins in induction of apoptosis mediated by microtubules targeting agents

Les agents anti-microtubules (MTAs), comme les taxanes et les vinca-alcaloïdes, sont des anticancéreux largement utilisés en pratique clinique. Ils agissent d'une part en perturbant les fonctions du réseau microtubulaire, conduisant à un arrêt du cycle cellulaire. D'autre part, à côté de cet effet anti-prolifératif, les MTAs sont capables d'induire divers signaux responsables de l'exécution du programme apoptotique via la voie mitochondriale intrinsèque. La famille Bcl-2 joue un rôle primordial dans l'induction de l'apoptose par ces agents. Aussi, au cours de ce travail, nous nous sommes d'abord intéressés à l'origine de la diminution de Bcl-2 lors de l'apoptose médiée par la vinorelbine. Nous avons ainsi mis en évidence la régulation transcriptionnelle de bcl-2 grâce à l'identification d'un nouveau site de liaison de p53 sur le promoteur de bcl-2. Dans un second temps, nous avons évalué l'influence de la famille Bcl-2 dans la réponse aux MTAs. En effet, nous nous sommes focalisés sur la sensibilité paradoxale aux MTAs de certaines tumeurs surexprimant Bcl-2, in vitro et in vivo chez la souris nude. Nous avons montré l'implication de Bim dans cette augmentation de sensibilité, qui agit en perturbant le réseau mitochondrial. Enfin, nous avons investigué le mécanisme moléculaire liant la surexpression de Bcl-2 et celle de Bim. Nous avons montré que la surexpression de Bcl-2, en inhibant l'activité transcriptionnelle de p53, permettait une meilleure activité du facteur de transcription FoxO3a, principal acteur de la régulation génique de Bim.Microtubule targeting agents (MTAs), such as taxanes and vinca-alkaloïds, are anticancer drugs widely used in clinical practice. Firstly, they are known to disturb functions of microtubular network, leading to cell cycle arrest. On the other hand, beside this anti-proliferative effect, MTAs are able to trigger signaling cascades leading to apoptosis execution, through intrinsic mitochondrial pathway. Bcl-2 family proteins play a crucial role in induction of MTAs-induced apoptosis. In this work, we first studied the origin of Bcl-2 downregulation in vinorelbine-mediated apoptosis. We thus highlighted a transcriptional mechanism through the identification of a novel p53 binding site in the bcl-2 promoter. Second, we evaluated the influence of Bcl-2 family in response to MTAs. Indeed, we focused on paradoxical sensitivity to MTAs of some tumors overexpressing Bcl-2, in vitro and in vivo in nude mouse. Bim was involved in this enhanced sensitivity, by disrupting the mitochondrial network. We then investigated the molecular mechanism linking Bcl-2 and Bim overexpressions. We showed that Bcl-2 overexpression, by inhibiting the transcriptional activity of p53, leads to an increase in activity of the transcription factor FoxO3a, the main actor in Bim transcriptional regulation. Our work underlines the importance of Bcl-2 family and especially Bim as potential biomarker in predicting MTA's efficacy

La tuberculose (une urgence mondiale)

DIJON-BU Médecine Pharmacie (212312103) / SudocSudocFranceF

Visual compatibility of defibrotide with selected drugs during simulated Y-site administration

International audienc

Bcl-2—Enhanced Efficacy of Microtubule-Targeting Chemotherapy through Bim Overexpression: Implications for Cancer Treatment

Bcl-2 is commonly overexpressed in tumors, where it is often associated with unfavorable outcome. However, it has also been linked to a favorable sensitivity to microtubule-targeting agents (MTAs). We show that Bcl-2– overexpressing lung and breast cancer cells were more sensitive to both paclitaxel and vinorelbine. Bcl-2 overexpression also significantly potentiated in vivo efficacy of paclitaxel, in terms of tumor volume decrease and survival benefits, in models of nude mice bearing lung cancer xenografts. To further investigate this favorable effect of Bcl-2, a genomic approach was taken. It revealed that Bcl-2 overexpression induced up-regulation of the proapoptotic protein Bim in lung cancer cells and that, conversely, Bcl-2 silencing decreased Bim expression level. A gene regulation study implicated the transcription factor Forkhead box-containing protein, class O3a in Bim up-regulation. Lastly, we show that Bim was responsible for MTA-triggered lung cancer cell death through a dynamin-related protein 1–mediated mitochondrial fragmentation. The Bcl-2–governed Bim induction evidence offers for the first time an explanation for the favorable higher sensitivity to treatment shown by Bcl-2–overexpressing cells. We suggest that Bim could be a powerful predictive factor for tumor response to MTA chemotherapy. Our data also give new insight into some failures in the efficacy of therapies targeted against Bcl-2

Stability of a highly concentrated solution of epirubicin for conventional transcatheter arterial chemoembolization

International audienc